| Particulars (Rupees in Crores.) | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 |
|---|---|---|---|---|---|
Gross Sales | 1,221 | 474.8 | 1,371.1 | 1,362.6 | 1,068.3 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,221 | 474.8 | 1,371.1 | 1,362.6 | 1,068.3 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 66.3 | 176.3 | 63.8 | 48.1 | 42 |
Total Income | 1,287.3 | 651.1 | 1,434.9 | 1,410.7 | 1,110.3 |
Total Expenditure | 672.9 | 436 | 566.8 | 557.8 | 571 |
PBIDT | 614.4 | 215.1 | 868.1 | 852.9 | 539.3 |
Interest | 10.2 | 4.4 | 4.1 | 5.2 | 6.2 |
PBDT | 604.2 | 210.7 | 864 | 847.7 | 533.1 |
Depreciation | 98.3 | 47 | 45.8 | 44.1 | 55.5 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 106.4 | 33.5 | 154.1 | 143.6 | 90.3 |
Deferred Tax | -6.5 | -2.2 | -12.4 | -8.5 | 1 |
Reported Profit After Tax | 406 | 132.4 | 676.5 | 668.5 | 386.3 |
Minority Interest After NP | -0.6 | -0.6 | -0.8 | 0 | 0 |
Net Profit after Minority Interest | 406.6 | 133 | 677.3 | 668.5 | 386.3 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 406.6 | 133 | 677.3 | 668.5 | 386.3 |
EPS (Unit Curr.) | 22.7 | 7.43 | 37.81 | 37.32 | 21.56 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 75 | 75 | 150 | 62.5 |
Equity | 35.8 | 35.8 | 35.8 | 35.8 | 35.8 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 50.31 | 45.3 | 63.31 | 62.59 | 50.48 |
PBDTM(%) | 49.48 | 44.37 | 63.01 | 62.21 | 49.9 |
PATM(%) | 33.25 | 27.88 | 49.33 | 49.06 | 36.16 |
In a statement, NATCO Pharma stated it is confident of addressing all the observations within the stated time frame.
Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.
Quarterly revenue came in at ₹1,287.3 crore, a 16% YoY increase from ₹1,110.3 crore in Q4 FY24, led by robust performance in key segments.
The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.
The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations
The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.
According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
